Visante: Stifling competition by drug manufacturers leads to high insulin prices
WASHINGTON — A highly consolidated insulin market limits competition and allows dramatic price increases on new and existing brand-name products, according to a new Visante analysis: “Insulins: Managing Costs with Increasing Manufacturer Prices.” The Visante analysis finds that insulin list prices escalated over the past 5-10 years largely due to limited competition caused by an